Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 7/20 | 0.50 |
| ▸ | ADH1B | P00325 | 2/20 | 0.50 |
| ▸ | ADH1C | P00326 | 2/20 | 0.50 |
| ▸ | ADH1A | P07327 | 2/20 | 0.50 |
| ▸ | ADH7 | P40394 | 2/20 | 0.50 |
| ▸ | ADH4 | P08319 | 1/20 | 0.50 |
| ▸ | S1PR2 | O95136 | 5/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 5/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 5/20 | 0.46 |
| ▸ | S1PR3 | Q99500 | 5/20 | 0.46 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5540551 | 1.00 | TSHR (0.54) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL6199529 | 1.00 | TSHR (0.54) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL6201052 | 1.00 | TSHR (0.54) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL6198021 | 0.94 | TSHR (0.50) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL5546229 | 0.89 | PAOX (0.45) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL10600362 | 0.89 | TSHR (0.56) | TSHRALDH1A1EPHX1ADH1BADH1C | |
| SCHEMBL55804 | 0.89 | TSHR (0.46) | TSHREPHX1ADH1BADH1CADH1A | |
| SCHEMBL156980 | 0.89 | TSHR (0.46) | TSHREPHX1ADH1BADH1CADH1A | |
| SCHEMBL77313 | 0.89 | TSHR (0.46) | TSHREPHX1ADH1BADH1CADH1A | |
| Hexyl Formate SCHEMBL59493 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | TSHR 319/4885ALDH1A1 355/4885EPHX1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.